Abstract:Protein kinases play important role in the regulation of various biological processes, and their malfunction and dysregulation are intricately linked to the initiation and progression of cancer. The effectiveness of small-molecule kinase inhibitors (KIs) has been well-established in the therapeutic landscape, with the FDA approving over 70 KIs for the treatment of cancer and other diseases. However, the widespread utilization of KIs has been accompanied by reported adverse events, prominently featuring cardiac complications, alongside hepatic and renal function. While many studies have indicated on-target and off-target kinase specificity associated with organ damage, there is an urgent need for building predictive models that can pinpoint which specific kinases might be involved in different types of organ injuries. Such a model would not only facilitate mechanistic elucidation but also serve as a valuable tool for preemptively identifying potential adverse events associated with KI treatment. In this study, we performed polypharmacology-based screening of kinase inhibitors in organotypic tissue slices prepared from the normal heart, liver, and kidney of three distinct species—human, canine, and rodents. These tissue samples were treated individually using a curated selection of 32 KIs that are representative of a larger set of KIs and collectively target most of the 'kinome.' Subsequently, we developed Elastic Net Regularization models by utilizing the kinase inhibition profiles of ~300 kinases. These models were used to predict changes in tissue viability, measured as a percentage change, following the treatment with the respective kinase inhibitors. Using these models, we predicted the toxicity of 428 kinase inhibitors, both as single agents and in pairwise combinations, against three organs—heart, liver, and kidney—in humans, rodents, or canines. Our data show that the models accurately predicted the renal and cardiac toxicity of many FDA-approved KIs that were previously known. For example, the inhibition of RET kinase was identified to be linked with renal toxicity. Further, we compared the toxicity landscape of kinase KIs among different species and identified distinct sets of kinases that were recognized as essential indicators of toxicity within the same organ across species. These disparities underscore the potential distinctions in organ metabolism. In summary, our data provide a comprehensive landscape of kinase inhibitor toxicity. Our models could serve as a valuable resource for predicting kinase inhibitor toxicity across species by leveraging inhibitor profile data. Citation Format: Yuqi Kang, Marina Chan, Songli Zhu, Taranjit S. Gujral. Integrating organotypic tissue slices and polypharmacology-based screening to map the toxicity landscape of kinase inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 616.

Cutaneous Toxicity of FDA-approved Small-Molecule Kinase Inhibitors

A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors

Hepatotoxicity of FDA-approved Small Molecule Kinase Inhibitors

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Kinase Inhibitors FDA-Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities

FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I

Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer

Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane

Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors

Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update

Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update

Recent advances in metabolism and toxicity of tyrosine kinase inhibitors

Delineating Drug Class and Target-Specific Adverse Events of Kinase Inhibitors

Abstract 616: Integrating organotypic tissue slices and polypharmacology-based screening to map the toxicity landscape of kinase inhibitors

Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management

Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System

Small Molecule Approaches to Treat Autoimmune and Inflammatory Diseases (part I): Kinase Inhibitors.

Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1

Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update

Reduced HMGB1 Expression Contributed to Lapatinib-Induced Cutaneous Injury